Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

141 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Design of OASIS 1 and 2: phase 3 clinical trials assessing the efficacy and safety of elinzanetant for the treatment of vasomotor symptoms associated with menopause.
Pinkerton JV, Simon J, Panay N, Seitz C, Parke S, Caetano C, Mellinger U, Haseli Mashhadi N, Haberland C, Atanackovic G, Holz C, Mao G, Morrison M, Nisius S, Schaefers M, Zuurman L. Pinkerton JV, et al. Among authors: caetano c. Menopause. 2024 Jun 1;31(6):522-529. doi: 10.1097/GME.0000000000002350. Epub 2024 Apr 3. Menopause. 2024. PMID: 38564691 Clinical Trial.
Efficacy and safety of elinzanetant, a selective neurokinin-1,3 receptor antagonist for vasomotor symptoms: a dose-finding clinical trial (SWITCH-1).
Simon JA, Anderson RA, Ballantyne E, Bolognese J, Caetano C, Joffe H, Kerr M, Panay N, Seitz C, Seymore S, Trower M, Zuurman L, Pawsey S. Simon JA, et al. Among authors: caetano c. Menopause. 2023 Mar 1;30(3):239-246. doi: 10.1097/GME.0000000000002138. Epub 2023 Jan 30. Menopause. 2023. PMID: 36720081 Free PMC article. Clinical Trial.
Elinzanetant for the Treatment of Vasomotor Symptoms Associated With Menopause: OASIS 1 and 2 Randomized Clinical Trials.
Pinkerton JV, Simon JA, Joffe H, Maki PM, Nappi RE, Panay N, Soares CN, Thurston RC, Caetano C, Haberland C, Haseli Mashhadi N, Krahn U, Mellinger U, Parke S, Seitz C, Zuurman L. Pinkerton JV, et al. Among authors: caetano c. JAMA. 2024 Aug 22;332(16):1343-54. doi: 10.1001/jama.2024.14618. Online ahead of print. JAMA. 2024. PMID: 39172446
Real-world evaluation of treatment utilization by women experiencing vasomotor symptoms associated with menopause in the United States and Europe: Findings from the REALISE study.
Kingsberg S, Banks V, Caetano C, Janssenswillen C, Moeller C, Schoof N, Harvey M, Scott M, Nappi RE. Kingsberg S, et al. Among authors: caetano c. Maturitas. 2024 Nov;189:108096. doi: 10.1016/j.maturitas.2024.108096. Epub 2024 Aug 22. Maturitas. 2024. PMID: 39208496 Free article.
Treatment utilization and non-drug interventions for vasomotor symptoms in breast cancer survivors taking endocrine therapy: Real-world findings from the United States and Europe.
Kingsberg S, Banks V, Caetano C, Janssenswillen C, Moeller C, Schoof N, Harvey M, Scott M, Nappi RE. Kingsberg S, et al. Among authors: caetano c. Maturitas. 2024 Oct;188:108071. doi: 10.1016/j.maturitas.2024.108071. Epub 2024 Jul 23. Maturitas. 2024. PMID: 39059108 Free article.
141 results